End-Of-Life-Considerations Fail To Save Lilly’s Alimta For NSCLC At NICE
This article was originally published in The Pink Sheet Daily
Executive Summary
Britain’s NICE has rejected Eli Lilly’s Alimta for non-small-cell lung cancer, citing cost-effectiveness issues. But the US drug maker still has options to get the drug approved by the pricing watchdog.
You may also be interested in...
Roche Won’t Match NICE's Excessive Discount Expectations For Kadcyla
A discount and even the fulfilment of end-of-life criteria have failed to save Kadcyla at NICE, putting the struggle between health systems’ sustainability and the need for R&D plus innovation in the spotlight.
Price Discount Paves The Way For NICE To Clear GSK’s Revolade
U.K. drug cost watchdog NICE has cleared Glaxo’s Revolade and Alcon's Jetrea but rejected Lilly's Alimta as maintenance therapy in a subgroup of lung cancer patients.
U.K. Provides £50 Million Extra For Cancer Drugs
Extra funds made available in the U.K. for anti-cancers turned down by NICE, with a £200 million fund to be set up next year.